Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q1 2025 value amounting to $72.1 million.

  • Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) rose 4708.11% to $72.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $72.1 million, marking a year-over-year increase of 4708.11%. This contributed to the annual value of $61.0 million for FY2024, which is 2698.56% up from last year.
  • Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $72.1 million in Q1 2025, which was up 4708.11% from $61.0 million recorded in Q4 2024.
  • Corvus Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $72.1 million during Q1 2025, with a 5-year trough of $46.6 million in Q1 2022.
  • In the last 4 years, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $47.5 million in 2023 and averaged $50.9 million.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) rose by 0.57% in 2023, and later skyrocketed by 4708.11% in 2025.
  • Quarter analysis of 4 years shows Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $46.6 million in 2022, then increased by 3.16% to $48.0 million in 2023, then grew by 26.99% to $61.0 million in 2024, then grew by 18.27% to $72.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $72.1 million in Q1 2025, compared to $61.0 million in Q4 2024 and $49.0 million in Q1 2024.